sue damage but also upregulates the inflammatory response through specific signaling mechanisms [5] . Recent reports have demonstrated that induced nitric oxide overproduction occurs in the liver of rats with CCl 4 -induced acute liver injury and suggested that iNOS may act as a mediator in the pathogenesis of hepatotoxicity in rats [6] [7] [8] .
Sparassis crispa, also known as cauliflower mushroom in English, is an edible mushroom with various medicinal properties that has recently been cultivated in Korea, China, and Japan. It is a brown root fungus that grows primarily on the stumps of coniferous trees [9] . Sparassis crispa has been reported to exhibit many biological activities, including tumor suppressive, anti-angiogenic, anti-allergic, and anti-diabetic effects [10, 11] . Moreover, the administration of soluble β-glucan preparation from Sparassis crispa has been found to modulate cytokine production in mice [12] . However, there is little information about the pharmacological action of this mushroom on acute liver injury caused by CCl 4 .
The aim of our study is to evaluate the protective effect of Sparassis crispa against CCl 4 -induced hepatotoxicity and to elucidate the possible mechanisms underlying these defensive effects in rats. The effect of Sparassis crispa on CCl 4 -induced acute liver injury was also compared to the effect of silymarin.
Materials and Methods

Ethics statements
All experiments were approved by Institutional Animal Care and Use Committee of Yanbian University School of Medical Sciences, and were in accordance with the Guide for the Care and Use of Laboratory Animals, published by the National Institutes of Health (NIH Publication 82-23, revised 1996) as well as ARRIVE (Animal Research: Reporting In Vivo Experiments) guidelines, produced by the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs). All surgery was performed under ethyl ether anesthesia, and all efforts were made to minimize suffering.
Preparation of Sparassis crispa ethanol extract (SCE)
The dried fruiting bodies of Sparassis crispa were purchased from the Hangzhou Xueyu Biological Technology Co., Ltd (Zhejiang, China). The voucher specimens were deposited in the College of Pharmacy, Yanbian University. The active Sparassis crispa was isolated using ethanol precipitation methods. Briefly, Sparassis crispa was soaked into 50% ethanol and boiled at 90� C for 4 h and filtered through a 270-mesh sieve. The sludge from the primary extraction was then extracted twice using the same procedure and evaporated to dryness with a rotary vacuum evaporator (Yiheng Technology Ltd., Shanghai, China) at 40� C under reduced pressure. The yield was 22% of the raw Sparassis crispa. The extract filtered with 0.2 μm syringe filter was adjusted with 0.5% carboxy methyl cellulose (CMC, Sigma, St. Louis, MO, USA) solution to give a stock solution in 10 mg/mL for experimental use. The solution was stored at 4� C until use.
Animals and treatment regimens
Male Sprague Dawley rats (house section of Yanbian University Health Science Center, China) weighing 180-200 g were used throughout the experiment. Animals were housed under standard environmental conditions (23±1� C, 55±5% humidity, and a 12 h light: 12 h dark cycle) and maintained with free access to water and a standard laboratory diet ad libitum. A total of 50 rats were assigned to five groups as follows group I, normal control rats with an intraperitoneal (i.p.) 0.5% CMC (vehicle) pretreatment and olive oil (Wako Pure Chemical Ind., Osaka, Japan) treatment; group II, the model group with an i.p. 0.5% CMC and CCl 4 (Merck, Darmstadt, Germany) treatment; group III, the low-dose SCE group with an i.p. 100 mg/kg SCE and CCl 4 treatment; group IV, the high-dose SCE group with an i.p. 200 mg/kg SCE and CCl 4 treatment; group V, the silymarin group with an i.p. 50 mg/kg silymarin (Sigma) and CCl 4 treatment. All rats were pretreated with the vehicle, SCE, or silymarin suspension daily for a period of 5 d. The SCE or silymarin suspension for i.p. administration was prepared by suspending in 0.5% CMC. At 1 h after the last pretreatment, 50% CCl 4 in olive oil was given intraperitoneally to the rats of groups II~V at a dose of 1 mL/kg of body weight, while olive oil (vehicle) was injected to group I. Rats were anesthetized with ethyl ether and blood was collected from the abdominal aorta 16 h after CCl 4 administration. All animals were killed by decapitation at the end of the experiment. For each rat, the liver was isolated and stored at -70� C for later analysis, except for the part in the left lobe, which was used for histological analysis.
Assessment of serum aminotransferase activities
The serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities were determined using a Hitachi 747 automatic analyzer (Hitachi, Tokyo, Japan).
Serum TNF-α α assay
The serum concentration of TNF-α was measured by using a rat TNF-α ELISA kit (eBioscience, San Diego, CA, USA) according to the corresponding protocol.
Oxidative damage assay
Hepatic malondialdehyde (MDA), a degrading product of lipid peroxidation known as thiobarbituric acid-reactive substances (TBARS), was also determined according to the thiobarbituric acid methods using an MDA test kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China).
Antioxidative enzyme assays
Hepatic antioxidative defense enzymes including superoxide dismutase (SOD) and catalase (CAT) were assayed by using SOD and CAT detection kits (Nanjing Jiancheng Bioengineering Institute).
Hepatic nitrite estimation
Hepatic nitrite level was estimated enzymatically with a colorimetric nitrite detection kit (Nanjing Jiancheng Bioengineering Institute).
Western blot immunoassay
Freshly isolated liver tissue was homogenized in a lysis buffer. A 20 μg sample of protein from the liver homogenates was loaded per lane on 7.5% or 10% polyacrylamide gels. Electrophoresis was then performed. The proteins were then transferred to nitrocellulose membranes. Western blot analysis was performed using the polyclonal antibodies against rat inducible nitric oxide synthase (iNOS; Transduction Laboratories, San Jose, CA, USA), cyclooxygenase-2 (COX-2; Cayman, Ann Arbor, MI, USA), Glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Santa Cruz Biochemicals, Santa Cruz, CA, USA), and goat polyclonal anti-rat CYP 2E1 antibody (Chemicon Co., Temecula, CA, USA). The binding of all the antibodies was detected using an ECL detection system (iNtRON Biotechnology Co., Ltd., Seoul, Korea), according to the manufacturer's instructions. The intensity of the immunoreactive bands was determined using a densitometric analysis program (Image Gauge V3. 12; Fuji Photo Film Co., Ltd., Tokyo, Japan).
Histological analysis
Twenty-four hours after administering CCl 4 , a small piece of liver tissue from the anterior portion of the left lateral lobe was removed for histological analysis. The sample was fixed by immersing it in 10% neutral-buffered formalin. The sample was then embedded in paraffin, sliced into 5 μm sections, and stained with hematoxylin-eosin for a blinded histological assessment. The histological changes were evaluated in nonconsecutive, randomly chosen ×100 histological fields.
Statistics
All the results are reported as the means ± SEM. The overall significance of the data was examined by one-way analysis of variance (ANOVA). The differences between the groups were considered significant at p⁄0.05 with the appropriate Bonferronic correction made for multiple comparisons. Fig. 1 showed that the rats of the model group (group II) induced with a single dose of CCl 4 developed hepatic damage as compared with the normal control group (group I). This was evident from marked modifications of liver function parameters AST and ALT in the serum. SCE and silymarin administration showed a significant reduction in AST and ALT activities as compared with the CCl 4 -intoxicated model group. In the rats of groups III and IV, the intraperitoneal administration of SCE at doses of 100 and 200 mg/kg prior to the CCl 4 challenge was observed to dose-dependently reverse the CCl 4 -induced alteration of AST and ALT. The CCl 4 treatment also induced an increase in the serum TNF-α level as compared to the normal control group. However, the serum TNF-α level in both SCE and silymarin-supplemented groups was significantly lower than that in the CCl 4 -treated group. In addition, SCE alone did not alter the serum TNF-α concentration (data not shown).
Results
Serum aminotransferase activities and TNF-α α levels
Lipid peroxidation and antioxidative enzyme system
An expected increase of the hepatic lipid peroxidative index in the CCl 4 -treated model group also confirmed that (Fig. 2) . When CCl 4 was injected into the rats that had been pretreated with SCE or silymarin, the level of MDA in the liver were significantly lower than that in the CCl 4 -treated model group. The observed suppression of oxidative damage in the CCl 4 -injured liver by SCE administration suggests that SCE was antioxidative and hepatoprotective. On the other hand, CCl 4 also induced substantial modifications to the hepatic antioxidative enzymes (Fig. 2) . The data show that the decrease levels of hepatic SOD and CAT activity as the result of CCl 4 injection were significantly elevated in SCE and silymarin groups.
Hepatic nitrite level
CCl 4 -induced hepatotoxicity is accompanied by the production of pro-inflammatory mediator such as iNOS. A significant rise in the hepatic nitrite level was observed in CCl 4 -induced animals when compared with control rats. However, the rats pretreated with SCE or silymarin showed a decreased nitrite level compared with the model animals ( Fig. 3 ).
Hepatic iNOS and COX-2 protein expression
Western blot analysis also revealed that the amount of hepatic iNOS and COX-2 proteins increased considerably after the CCl 4 administration. However, the increase in iNOS and COX-2 protein levels was significantly attenuated by SCE or silymarin (Fig. 4) . SCE treatment alone did not alter the protein levels of iNOS and COX-2 (data not shown). 
Hepatic microsomal P450 2E1 protein expression
Fig . 5 shows the protein expression of cytochrome P450 (CYP) 2E1 in the liver microsomes. Compared to the normal control group, the rats receiving CCl 4 alone showed a significant decrease in the CYP2E1 protein level. In contrast, in the rats pretreated with SCE or silymarin, a higher level of CYP2E1 was found than that in the rats intoxicated with CCl 4 alone. The restoration of CYP2E1 by SCE supplementation implies that SCE could have a hepatoprotective effect which led to rapid recovery from CCl 4 -induced liver injury.
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Histological analysis
A liver tissue section from normal rats is shown in Fig.  6A . In rats receiving CCl 4 alone, the liver histology at 16 h after CCl 4 exposure showed extensive hepatocellular damage such as hepatosteatosis and inflammation, which was evidenced by the presence of hepatocyte lipid vacuolation and infiltrating lymphocyte-rich mononuclear cells around vena centralis (Fig. 6B) . These histopathological changes were ameliorated by both SCE (100 and 200 mg/kg) and silymarin (50 mg/kg) treatments (Fig. 6C, D , and E).
Discussion
Acute and chronic liver diseases constitute a global concern, and the medical treatments for these diseases are often difficult to handle and have limited efficacy. Therefore, there has been considerable interest in the role of complementary and alternative medicines for treatment of liver diseases [13] . Developing therapeutically effective agents from natural products may reduce the risk of hepatotoxicity when the drug is used clinically. The present in vivo study has demonstrated the hepatoprotective potential of Sparassis crispa.
Liver injury induced by CCl 4 is a common model for screening the hepatoprotective activity of drugs because this chemical is a potent hepatotoxin and a single exposure can rapidly lead to severe hepatic necrosis and steatosis [2, 14] . Increases in serum AST and ALT levels by CCl 4 have been attributed to hepatic structural damage because these enzymes are normally localized to the cytoplasm and released into the circulation after cellular damage has occurred [14] . The present study showed that SCE significantly preserves the structural integrity of the hepatocellular membrane and suppresses CCl 4 -induced hepatic injury, as demonstrated by the reduction in serum marker enzyme activities. This phenomenon was also supported by histological examinations. In this study, CCl 4 caused a variety of histological changes to the liver, including hepatosteatosis and inflammation. These changes were significantly attenuated by SCE. Furthermore, the hepatoprotective effect of SCE seemed to be as beneficial as that of silymarin, which has been used as a potent hepatoprotective agent. Therefore, it is suggested that SCE may have potential clinical application for treating liver diseases.
It is generally accepted that the hepatotoxicity of CCl 4 is the result of reductive dehalogenation. Lipid peroxidation is accepted to be one of the principal causes of CCl 4 -induced liver injury and is mediated by the production of free radical derivatives of CCl 4 . Therefore, antioxidant activity and/or the inhibition of free radical generation are important in terms of protecting the liver from CCl 4 -induced damage [2] . In general, antioxidative enzymes such as SOD and CAT are easily inactivated by lipid peroxides or reactive oxygen species (ROS), which results in decreased activities of these enzymes in CCl 4 toxicity [1] . Our results showed that, in parallel with the alteration in serum marker enzymes, increased level of lipid peroxidation (MDA) as well as decreased activities of SOD and CAT occurred in liver injury induced by CCl 4 , implying downregulation of numerous antioxidative reactions in liver. SCE pretreated animals showed a significant reduction in the level of the hepatic peroxidative marker (MDA) with concomitant improvement in the hepatic antioxidative defense system. This suggests that SCE may be able to protect against the oxidative damage of hepatic cellular membrane via a free radical scavenging property.
The results also show that SCE suppresses an increase in the serum TNF-α level. TNF-α is a pro-inflammatory cytokine produced predominantly by macrophage and plays a key role in the host defense response to injury and infection. While low levels of TNF-α may play a role in cell protection, excessive amounts cause cell impairment. An increase in the TNF-α level has been directly correlated with the histological evidence of hepatic necrosis and the elevation in the serum aminotransferase levels [15] . DeCicco et al. have reported the stimulation of TNF-α production in both serum and liver following CCl 4 administration, and it is suggested that CCl 3 • activates Kupffer cells to release TNF-α [16] . In this study, the hepatic expression of TNF-α increased abnormally in CCl 4 -administered animals. The SCE pretreatment inhibited the elevated TNF-α production following CCl 4 injection, and the low level of TNF-α might have played a protective role in this model by inducing hepatocyte proliferation and the release of mediators involved in tissue repair. The inhibitory capacity of SCE appears to be related to suppression of the production of TNF-α from Kupffer cells. Further studies may be needed to elucidate this phenomenon.
TNF-α also stimulates the release of cytokines from macrophages and induces phagocyte oxidative metabolism and nitric oxide production [17] . Nitric oxide can exacerbate oxidative stress by reacting with ROS, particularly with the superoxide anion, and forming peroxynitrite [18] . However, the role of nitric oxide in liver damage remains controversial [5, 19] . Although several studies have found that nitric oxide protects against CCl 4 -induced liver injury using NOS knockout mice or a NOS inhibitor, certain evidence has addressed that excessive nitric oxide production by iNOS may lead to hepatic injury [6, 18, 20, 21] . The current study confirmed significant increases in hepatic nitrite level and iNOS protein expression after CCl 4 administration. As the augment in hepatic nitrite content was dose-dependently attenuated by SCE, the extent of suppression of iNOS levels was evaluated by using both SCE (200 mg/kg) and a reference drug, silymarin (50 mg/kg). The observed repression of iNOS expression by SCE suggests that SCE inhibits iNOS protein secretion and/or enhances the degradation of these proteins. Accordingly, the possible mechanism of protection against CCl 4 -induced hepatotoxicity appears to be, at least in part, due to the decreased hepatic nitric oxide production.
Previous studies have reported that the induction of cyclooxygenase in inflammatory response is the secondary effect of CCl 4 -induced hepatotoxicity [1] . COX-2 is thought to be the predominant cyclooxygenase involved in the inflammatory responses [22] . There is considerable evidence suggesting that COX-2 is upregulated in several pathological conditions including cancer and autoimmune disease [23] . In other words, the reduction in excss nitric oxide generation as well as inhibition of iNOS and COX-2 protein expression may be associated with the prevention and treatment of the oxidative stress-induced inflammatory diseases. Our data showed an increase in the expression of COX-2 protein after CCl 4 administration. SCE attenuated this increase, suggesting a suppression of inflammatory responses.
Generally, CCl 4 is metabolized to highly reactive trichloromethyl-free radicals mainly by the CYP system in the endoplasmic reticulum of hepatic cells [24] . However, the trichloromethyl radical may bind either at the haem group of CYP or at the active site of the enzyme near the haem group, leading to the inactivation of CYP pathways [25] . In the present study, a significant decrease in hepatic CYP2E1 function was found in the rats treated with CCl 4 alone. In contrast, in rats pretreated with SCE, the hepatic CYP2E1 function was less suppressed after CCl 4 administration. This result proposes that SCE exerts a beneficial effect on hepatic CYP2E1 restoration in this animal model. Therefore, it is possible that SCE restores the hepatic CYP2E1 function and leads to a rapid recovery from CCl 4 -induced liver injury. On the other hand, it is also likely that the administration of SCE causes a reduction in CCl 4 -induced hepatotoxicity that leads to an early recovery of the CYP2E1 function in the animal model, which would give rise to an elevation of the enzyme activity. With regard to this phenomenon, future work may be needed.
More recently, the water extract of Sparassis crispa has been shown to increase inhibitory kappa B-alpha and to reduce nuclear factor-kappa B (NF-κB) levels in activated mast cells, suggesting the possibility that Sparassis crispa could regulate the NF-κB activity in a variety of cell types [11] . However, the role of NF-κB in liver damage remains controversial. While it has been shown that NF-κB activation promotes cell survival in TNF-α-induced hepatotoxicity [26] , studies have also indicated that NF-κB is an important regulator of numerous inflammatory mediators, several of which have been implicated in drug-induced hepatotoxicity [27, 28] . On the basis of these observations, it is reasonable to speculate that Sparassis crispa may protect against hepatotoxicity by exerting anti-NF-κB actions. However, there is no evidence to support these assumptions in liver damages. Therefore, anti-NF-κB actions of Sparassis crispa in liver injury should be addressed in the future study.
In conclusion, our work demonstrates that SCE protects the liver from CCl 4 -induced acute hepatic damage, which might be due to its ability to restore the CYP2E1 function and suppress the inflammatory responses, in combination with its capacity to reduce oxidative stress. The potential for using Sparassis crispa in experimental and practical applications should be examined further.
